Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vitro immune characterization of ISA106 SARS-CoV-2 peptide vaccine candidates
NL-OMON50131Completed
- Sponsor
- ISA Pharmaceuticals
- Start
- Aug 2020
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ISA106 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by ISA Pharmaceuticals. Primary endpoint: Memory T-cell response to each candidate peptide. Started Aug 2020; status: completed.
02
Drugs
ISA106
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50131.